hCMV-Mediated Immune Escape Mechanisms Favor Pathogen Growth and Disturb the Immune Privilege of the Eye.
Cell Proliferation
/ genetics
Coinfection
/ immunology
Cytomegalovirus
/ genetics
Eye
/ immunology
Flow Cytometry
Humans
Immune Privilege
/ genetics
Indoleamine-Pyrrole 2,3,-Dioxygenase
/ genetics
Interferon-gamma
/ immunology
Nitric Oxide Synthase Type II
/ genetics
Retinal Pigment Epithelium
/ immunology
Staphylococcus aureus
/ growth & development
T-Lymphocytes
/ immunology
Toxoplasma
/ growth & development
Uveitis
/ immunology
Indoleamine 2,3-dioxygenase-1
Staphylococcus aureus
Toxoplasma gondii
chorioretinitis
human cytomegalovirus
human retinal pigment epithelial cells
inducible nitric oxide synthase
ocular toxoplasmosis
retinitis
uveitis
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
16 Feb 2019
16 Feb 2019
Historique:
received:
15
01
2019
revised:
05
02
2019
accepted:
12
02
2019
entrez:
21
2
2019
pubmed:
20
2
2019
medline:
30
5
2019
Statut:
epublish
Résumé
Human retinal pigment epithelial (hRPE) cells are important for the establishment and maintenance of the immune privilege of the eye. They function as target cells for human cytomegalovirus (hCMV), but are able to restrict viral replication. hCMV causes opportunistic posterior uveitis such as retinitis and chorioretinitis. Both mainly occur in severely immunocompromised patients and rarely manifest in immunocompetent individuals. In this study, hRPE cells were infected with hCMV in vitro and activated with proinflammatory cytokines. The enzymatic activities of indoleamine 2,3-dioxygenase-1 (IDO1) and inducible nitric oxide synthase (iNOS) were determined. The antimicrobial capacity of both molecules was analyzed in co-infection experiments using
Identifiants
pubmed: 30781494
pii: ijms20040858
doi: 10.3390/ijms20040858
pmc: PMC6413209
pii:
doi:
Substances chimiques
IDO1 protein, human
0
Indoleamine-Pyrrole 2,3,-Dioxygenase
0
Interferon-gamma
82115-62-6
Nitric Oxide Synthase Type II
EC 1.14.13.39
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Jürgen Manchot Stiftung
ID : MOI III
Références
J Exp Med. 1999 May 3;189(9):1363-72
pubmed: 10224276
Infect Immun. 1999 Nov;67(11):5615-20
pubmed: 10531207
J Gen Virol. 1999 Nov;80 ( Pt 11):2867-77
pubmed: 10580048
Infect Immun. 2004 May;72(5):2723-30
pubmed: 15102781
Curr Eye Res. 2005 May;30(5):375-83
pubmed: 16020268
Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4654-63
pubmed: 17898289
J Gen Virol. 2008 Feb;89(Pt 2):359-68
pubmed: 18198366
FEMS Immunol Med Microbiol. 2008 Mar;52(2):273-81
pubmed: 18205804
J Gen Virol. 2008 Oct;89(Pt 10):2416-26
pubmed: 18796709
J Immunol. 2008 Oct 15;181(8):5530-6
pubmed: 18832710
Thromb Haemost. 2009 Dec;102(6):1110-6
pubmed: 19967141
Ocul Immunol Inflamm. 2010 Jan;18(1):24-31
pubmed: 20128646
Rev Med Virol. 2010 Jul;20(4):202-13
pubmed: 20564615
J Clin Invest. 2010 Sep;120(9):3073-83
pubmed: 20811163
J Protozool. 1977 Aug;24(3):449-53
pubmed: 21288
Eye (Lond). 2012 Feb;26(2):237-40
pubmed: 22173076
PLoS One. 2013 May 15;8(5):e64442
pubmed: 23691219
Invest Ophthalmol Vis Sci. 2013 Oct 23;54(10):6926-33
pubmed: 24065812
J Gen Virol. 2014 Mar;95(Pt 3):659-70
pubmed: 24337170
Int J Med Microbiol. 2014 Oct;304(7):917-29
pubmed: 25240467
Ophthalmic Res. 2014;52(3):116-23
pubmed: 25248050
J Exp Med. 2016 Aug 22;213(9):1835-50
pubmed: 27503073
Surv Ophthalmol. 2017 Jul - Aug;62(4):404-445
pubmed: 28012878
Semin Perinatol. 2018 Apr;42(3):149-154
pubmed: 29503048
Biol Blood Marrow Transplant. 2018 Sep;24(9):1776-1782
pubmed: 29626514
Curr Opin Ophthalmol. 2018 Jul;29(4):373-377
pubmed: 29708927
J Immunol Res. 2018 May 20;2018:1679197
pubmed: 29888291
PLoS One. 2018 Jul 25;13(7):e0200267
pubmed: 30044826
Curr Opin Ophthalmol. 2018 Nov;29(6):558-565
pubmed: 30169465
Int J Mol Sci. 2018 Sep 18;19(9):null
pubmed: 30231586
Biol Blood Marrow Transplant. 2018 Oct 18;:null
pubmed: 30342913
J Immunol. 1988 Oct 1;141(7):2407-12
pubmed: 3139757
J Immunol Methods. 1994 Jan 12;168(1):39-47
pubmed: 8288893
Infect Immun. 1996 Oct;64(10):4188-96
pubmed: 8926087
J Exp Med. 1998 Mar 2;187(5):675-83
pubmed: 9480977
J Immunol. 1999 Jan 15;162(2):957-64
pubmed: 9916720